No connection

Search Results

OGI vs PRQR

OGI
Organigram Global Inc.
BEARISH
Price
$1.52
Market Cap
$209.6M
Sector
Healthcare
AI Confidence
85%
PRQR
ProQR Therapeutics N.V.
BEARISH
Price
$1.99
Market Cap
$209.7M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
OGI
13.82
PRQR
--
Forward P/E
OGI
84.44
PRQR
-4.23
P/B Ratio
OGI
0.77
PRQR
3.63
P/S Ratio
OGI
0.75
PRQR
12.83
EV/EBITDA
OGI
47.95
PRQR
-3.13

Profitability

Gross Margin
OGI
35.61%
PRQR
100.0%
Operating Margin
OGI
-5.38%
PRQR
-192.9%
Profit Margin
OGI
6.49%
PRQR
-258.05%
ROE
OGI
4.64%
PRQR
-61.17%
ROA
OGI
-1.47%
PRQR
-19.35%

Growth

Revenue Growth
OGI
48.7%
PRQR
6.1%
Earnings Growth
OGI
--
PRQR
--

Financial Health

Debt/Equity
OGI
0.02
PRQR
0.32
Current Ratio
OGI
2.73
PRQR
3.09
Quick Ratio
OGI
0.62
PRQR
3.0

Dividends

Dividend Yield
OGI
--
PRQR
--
Payout Ratio
OGI
0.0%
PRQR
0.0%

AI Verdict

OGI BEARISH

OGI exhibits severe financial fragility, highlighted by a weak Piotroski F-Score of 2/9 and a negative operating margin of -5.38%. While the stock appears undervalued relative to its Graham Number ($2.21) and Price-to-Book ratio (0.77), the intrinsic value is significantly lower at $0.77. Strong top-line revenue growth of 48.7% is currently offset by a poor earnings track record and a concerning spike in Forward P/E (from 13.82 to 84.44), suggesting a projected collapse in earnings. The company is essentially a speculative play on revenue growth that has yet to prove operational sustainability.

Strengths
Strong YoY revenue growth of 48.70%
Very low leverage with a Debt/Equity ratio of 0.02
Trading below book value (P/B 0.77)
Risks
Critical financial health weakness (Piotroski F-Score 2/9)
Negative operating margin (-5.38%) indicating core business losses
Severe earnings volatility with an average surprise of -949.02% over the last 4 quarters
PRQR BEARISH

The deterministic health profile is critical, highlighted by a Piotroski F-Score of 0/9, indicating severe fundamental weakness across all measured financial dimensions. While the company maintains a strong liquidity position with a Current Ratio of 3.09 and low Debt/Equity (0.32), it suffers from extreme operational inefficiency with a profit margin of -258.05%. There is a stark divergence between the objective financial data and the 'Strong Buy' analyst consensus, suggesting the valuation is based on speculative pipeline catalysts rather than current fiscal performance. The technical trend is entirely bearish (0/100), further compounding the negative outlook.

Strengths
Strong short-term liquidity (Current Ratio 3.09)
Low leverage (Debt/Equity 0.32)
Strong analyst conviction with a target price of $8.88
Risks
Critical fundamental failure (Piotroski F-Score 0/9)
Extreme negative profitability (Profit Margin -258.05%)
High valuation relative to sales (P/S 12.83)

Compare Another Pair

OGI vs PRQR: Head-to-Head Comparison

This page compares Organigram Global Inc. (OGI) and ProQR Therapeutics N.V. (PRQR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile